LGND Share Price

Open 103.11 Change Price %
High 105.68 1 Day 0.63 0.61
Low 102.15 1 Week -2.65 -2.48
Close 104.12 1 Month 12.96 14.22
Volume 191865 1 Year -0.67 -0.64
52 Week High 139.79
52 Week Low 0.00
LGND Important Levels
Resistance 2 107.39
Resistance 1 106.04
Pivot 103.98
Support 1 102.20
Support 2 100.85
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

LGND Technical Analysis 1.5
As on 2nd Dec 2016 LGND Share Price closed @ 104.12 and we RECOMMEND Sell for LONG-TERM with Stoploss of 109.29 & Buy for SHORT-TERM with Stoploss of 101.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
LGND Target for December
1st Target up-side 117.19
2nd Target up-side 126.11
3rd Target up-side 135.02
1st Target down-side 91.77
2nd Target down-side 82.85
3rd Target down-side 73.94
LGND Other Details
Segment EQ
Market Capital 357465760.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ligand.com
LGND Address
LGND
11119 North Torrey Pines Road
Suite 200
La Jolla, CA 92037
United States
Phone: 858-550-7500
LGND Latest News
Interactive Technical Analysis Chart Ligand Pharmaceuticals Incorporated ( LGND NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ligand Pharmaceuticals Incorporated
LGND Business Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company�s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer�s VFEND IV and Baxter International�s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer�s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It�s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. On January 26, 2011, the Company acquired CyDex Pharmaceuticals, Inc. (CyDex).